BackEiger BioPharmaceuticals Overview

Eiger BioPharmaceuticals Total Assets

Track Eiger BioPharmaceuticals's total assets ($39M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$38.83M
67.68% YoYΔ $-81.31M vs prior year quarter

Peer average / median

Loading

Eiger BioPharmaceuticals Total Assets History

Loading

Eiger BioPharmaceuticals vs. peers: Total Assets Comparison

Loading

Eiger BioPharmaceuticals Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eiger BioPharmaceuticals (EIGRQ) FAQ

The latest total assets for EIGRQ is $39M as of December 2023. That compares with $120M in the prior-year period — down 67.7% year over year. Investors often review this figure alongside Eiger BioPharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, EIGRQ's total assets moved from $120M to $39M — a 67.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eiger BioPharmaceuticals's operating scale or balance-sheet position.

A total assets figure of $39M for EIGRQ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EIGRQ's total assets ($39M), review year-over-year change from $120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Eiger BioPharmaceuticals's total assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.